Oncology, CNS Agents May Dominate 2006 NME Approvals; 2005 Total Is 18
Executive Summary
The first half of 2006 could bring at least five novel oncologic approvals, including three for hematologic cancers
You may also be interested in...
First Cycle Approval Rate Tops 50% For 2006 NMEs; Merck Hits 100%
Merck skillfully navigated FDA's approval process in 2006, receiving all five of its new molecular entity and novel biologic approvals after only a single review cycle
First Cycle Approval Rate Tops 50% For 2006 NMEs; Merck Hits 100%
Merck skillfully navigated FDA's approval process in 2006, receiving all five of its new molecular entity and novel biologic approvals after only a single review cycle
2007 NME Prospects Plentiful For Wyeth, Novartis – Other Firms Fall Short
The year 2007 holds the potential to fatten Wyeth's new drug lineup: after a lean 2006, when no Wyeth new molecular entities were approved, the company leads the industry in potential NME approvals for the coming year